Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

By Hofer Silvia   Elandt Katarzyna   Greil Richard   Hottinger Andreas F.   Huber Urs   Lemke Dieter   Marosi Christine   Ochsenbein Adrian   Pichler Josef   Roelcke Ulrich   Weder Patrik   Zander Thilo   Wick Wolfgang   Weller Michael  

Acta Oncologica, Vol. 50, Iss. 5, 2011-06 ,pp. : 630-635

Informa Healthcare

Access to resources Recommend Favorite

Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option

By Flieger Maya   Ganswindt Ute   Schwarz Silke   Kreth Friedrich-Wilhelm   Tonn Jörg-Christian   Fougère Christian   Ertl Lorenz   Linn Jennifer   Herrlinger Ulrich   Belka Claus   Niyazi Maximilian  

Journal of Neuro-Oncology, Vol. 117, Iss. 2, 2014-04 ,pp. : 337-345

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

By Zuniga R.   Torcuator R.   Jain R.   Anderson J.   Doyle T.   Ellika S.   Schultz L.   Mikkelsen T.  

Journal of Neuro-Oncology, Vol. 91, Iss. 3, 2009-02 ,pp. : 329-336

Springer Publishing Company

Access to resources Recommend Favorite

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

By Zuniga Richard   Torcuator Roy   Jain Rajan   Anderson John   Doyle Thomas   Schultz Lonni   Mikkelsen Tom  

Journal of Neuro-Oncology, Vol. 99, Iss. 2, 2010-09 ,pp. : 237-242

Springer Publishing Company

Access to resources Recommend Favorite

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07

By                      

Oncology Reports, Vol. 28, Iss. 2, 2012-01 ,pp. : 654-658

Spandidos Publications

Access to resources Recommend Favorite